ArticleNature reviews. Clinical oncology2024
Two decades of advances in clinical oncology - lessons learned and future directions.
Abstract read
In one paragraph
Article in Nature reviews. Clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Nanomedicine-based cancer immunotherapy: translational barriers, mechanistic strategies, and future perspectives.Drug delivery · 2026Review
- Reprogramming of TLR-Ferroptosis Signaling and Immunometabolic Pathways Overcomes Myeloid Suppression to Improve Checkpoint Blockade in Prostate Cancer.Cancer research · 2026Article
- Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.Nature reviews. Clinical oncology · 2026Article
- Immunohistochemistry (IHC) Versus Genomic Profiling in Cancer: Roles in Precision Medicine.Cureus · 2026Review
- Explainable AI reveals squamous histology and U-shaped PD-L1 patterns as primary subgroup predictors of neoadjuvant and perioperative immunotherapy benefit in NSCLC: a machine learning analysis.Cancer immunology, immunotherapy : CII · 2026Article
- NKG2A inhibition promotes NK cell-CD8Nature communications · 2026Article
- Multimodal artificial intelligence and machine learning in oncology: from data integration to precision cancer care.Frontiers in digital health · 2026Review
- Promising Role of PKM2 in the Diagnosis and Prognosis of Ovarian Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Continuous adaptive chemotherapy dosing by using planet-formation-inspired dynamics: analytical andFrontiers in oncology · 2026Article
- Hepatocellular carcinoma: Epidemiology, diagnosis and treatment.JHEP reports : innovation in hepatology · 2025Review
- Two Decades of Disease Evolution and Biomarker-Guided Clinical Decision Making in Metastatic Prostate Cancer.International journal of molecular sciences · 2025Article
- Diverse RNA methylation patterns in neutrophils: key drivers in hepatocellular carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- T-Cell Engager Therapy in Prostate Cancer: Molecular Insights into a New Frontier in Immunotherapy.Cancers · 2025Review
- Diagnosis and management of cancer recurrence: a clinical update for GPs.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025Article
- The treatment of breast cancer in the era of precision medicine.Cancer biology & medicine · 2025Review
- Cancer complexity: why we need a novel cancer research strategy.Frontiers in oncology · 2025Article
- Cancer genomics and bioinformatics in Latin American countries: applications, challenges, and perspectives.Frontiers in oncology · 2025Review
- Unraveling the Anti-Cancer Mechanisms of Antibiotics: Current Insights, Controversies, and Future Perspectives.Antibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Susana BanerjeeGynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK. Susana.Banerjee@rmh.nhs.uk.
Christopher M BoothDepartment of Oncology, Queen's University, Kingston, Ontario, Canada. Christopher.Booth@kingstonhsc.ca.
Eduardo BrueraDepartment of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer, Unit 1414, Houston, TX, USA. ebruera@mdanderson.org.
Markus W BüchlerBotton-Champalimaud Pancreatic Cancer, Champalimaud Foundation, Lisbon, Portugal. Markus.Buechler@med.uni-heidelberg.de.
Alexander DrilonMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. drilona@mskcc.org.ORCID http://orcid.org/0000-0001-6806-9061
Terry J FryDepartment of Paediatrics and Immunology, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Aurora, CO, USA. terry.fry@ucdenver.edu.
Irene M GhobrialCenter for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-7361-3092
Luca GianniGianni Bonadonna Foundation, Milan, Italy. luca.gianni@fgb-inst.org.ORCID http://orcid.org/0000-0002-2372-9625
Rakesh K JainHarvard Medical School and Massachusetts General Hospital, Boston, MA, USA. jain@steele.mgh.harvard.edu.
Guido KroemerCentre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France. kroemer@orange.fr.ORCID http://orcid.org/0000-0002-9334-4405
Josep M LlovetMount Sinai Liver Cancer Program, Divisions of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Josep.Llovet@mountsinai.org.ORCID http://orcid.org/0000-0003-0547-2667
Georgina V LongMelanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au.ORCID http://orcid.org/0000-0001-8894-3545
Klaus PantelInstitute of Tumour Biology, University Cancer Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany. pantel@uke.de.ORCID http://orcid.org/0000-0001-5736-2772
Kathy Pritchard-JonesUCL Great Ormond Street Institute of Child Health, University College London, London, UK. k.pritchard-jones@ucl.ac.uk.ORCID http://orcid.org/0000-0002-2384-9475
Howard I ScherGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. scherh@MSKCC.ORG.ORCID http://orcid.org/0000-0002-6791-9324
Josep TaberneroMedical Oncology Department, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain. jtabernero@vhio.net.
Ralph R WeichselbaumDepartment of Radiation and Cellular Oncology, Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL, USA. rweichselbaum@bsd.uchicago.edu.
Michael WellerDepartment of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland. michael.weller@usz.ch.ORCID http://orcid.org/0000-0002-1748-174X
Yi-Long WuGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. wuyilong@gdph.org.cn.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0MThe Role of KLF6 in Hepatic FibrosisR01DK056621 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI FRIEDMAN, SCOTT L. · 2000 to 2019
$6.2MTargeting physical stress-driven mechanisms to overcome glioblastoma treatment resistanceU01CA261842 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., MUNN, LANCE L. · 2021 to 2025
$3.1MHepatic stellate cells in NASH fibrosis and HCCR01DK128289 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCOTT L. FRIEDMAN · 2021 to 2026
$2.6MImproving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolismR01CA259253 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., VANDER HEIDEN, MATTHEW G. · 2021 to 2025
$2.3MDeterminants of immunotherapy response in NASH-Hepatocellular carcinomaR01CA273932 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JOSEP M LLOVET · 2023 to 2026
$2.0MReprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2R01NS118929 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI · 2021 to 2025
$2.0MReprogramming the tumormicroenvironment to improve immunotherapy of glioblastomaR01CA269672 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Rakesh K. Jain · 2022 to 2026
$1.9MHepatic autophagy, progenitor cells and fibrosisR56DK056621 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FRIEDMAN, SCOTT L. · 2015 to 2015
$297kNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA259253NCI NIH HHS R01 CA269672NCI NIH HHS R01 CA273932NCI NIH HHS U01 CA261842NIDDK NIH HHS R01 DK056621NIDDK NIH HHS R01 DK128289NIDDK NIH HHS R56 DK056621NINDS NIH HHS R01 NS118929
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.